Third. by Cuicui Liu (1496260)

Unadjusted mean (SD) volume (ml) of beer sold per day, overall and by serving size, and volume of wine (ml) sold of premises included in primary analysis (<i>n</i> = 12). by Eleni Mantzari (6991172)

Subjects:

Candidates from the RF method. The top 25 random forest candidates ranked by mean decrease in accuracy and mean decrease in Gini Index are in the first and second columns, respectively.... by Zoë Parker Cates (22184243)

“…The top 25 random forest candidates ranked by mean decrease in accuracy and mean decrease in Gini Index are in the first and second columns, respectively. …”

Dynamics of net spillage in the third stage (post epidemic). by Cuicui Liu (1496260)

Changes in total spillage during the third stage (post epidemic). by Cuicui Liu (1496260)

Heteroscedastic linear mixed model main results, estimating the volume (ml) of beer sold per day on the transformed (cube root) scale, on the original scale and on the relative sca... by Eleni Mantzari (6991172)

Subjects:

Additional file 7 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Additional file 3 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Dynamics of pairwise net spillovers between sectors in the third stage (post epidemic). by Cuicui Liu (1496260)

Mean 0-30 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI). by Murat Tutar (22250461)

Subjects:

Mean 0-20 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI). by Murat Tutar (22250461)

Subjects:

Mean 0-10 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI). by Murat Tutar (22250461)

Subjects:

Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

Subjects:

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, CRT (μm ± standard deviation) significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Geometric mean anti-<i>Na</i>-GST-1 IgG subclass levels over time. by David J. Diemert (8135568)

Subjects:

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”